Company intelligence / Profile preview

Portage Pharma

Road Town, British Virgin Islands

Ownership: Private
Development stage: Other

Overview

Clinical-stage immuno-oncology company with portfolio of 10 products in preclinical or clinical development targeting immune checkpoint resistance; reported net loss of $75.4M for FY ended March 31, 2024.

Therapeutic areas: OncologyOphthalmology
Modalities: Small moleculeIntratumoral therapyNanoparticleLiposomeAptamerVirus-like particle
Industry: Biotech

Partnerships

Intensity Therapeutics (clinical trial supply agreement)Immunova (letter of intent for option to acquire iOx Therapeutics)

Beyond the preview

Go deeper on Portage Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Portage Pharma.

Explore the full profile